Bionano Q2 2025 revenue $6.7M (-13% YoY); gross margin 52% vs 33%; flowcell sales +17%

Bionano Genomics, Inc.

2025-Q2 EPS reported -$3.24 vs consensus -$2.46 ▼ miss (-31.5%)

Total revenue $6.7M (-13% YoY); prior year included $0.7M discontinued clinical services; adjusted consumables/software/services up 11%.
Gross margin 52% (non-GAAP 52%) vs 33% a year ago; operating expenses cut 42% to $11.3M.
Sold 7,233 flowcells (+17% YoY); installed OGM base 378 systems (+4% YoY).
Full-year 2025 revenue reaffirmed $26-30M; Q3 2025 guidance $6.7-7.2M; cash runway into Q1 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.